<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954354</url>
  </required_header>
  <id_info>
    <org_study_id>1601T0831</org_study_id>
    <nct_id>NCT02954354</nct_id>
  </id_info>
  <brief_title>A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza</brief_title>
  <acronym>CAPSTONE 1</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single, oral dose of
      Baloxavir Marboxil compared with placebo by measuring the time to alleviation of symptoms in
      patients with uncomplicated influenza virus infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Actual">April 22, 2017</completion_date>
  <primary_completion_date type="Actual">April 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to alleviation of symptoms</measure>
    <time_frame>From Day 1 pretreatment (baseline) up to Day 14</time_frame>
    <description>Time to alleviation of symptoms is defined as the time between the initiation of the study treatment and the alleviation of influenza symptoms. The alleviation of influenza symptoms is defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient as being alleviated at each prespecified time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants positive for influenza virus titer at each time point</measure>
    <time_frame>Days 1, 2, 3, 5 and 9</time_frame>
    <description>Defined as the percentage of patients whose virus titer is not less than the lower limit of quantification among those assessed for virus titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants positive for influenza virus by RT-PCR at each time point</measure>
    <time_frame>Days 1, 2, 3, 5 and 9</time_frame>
    <description>Defined as the percentage of patients with detectable virus ribonucleic acid (RNA) measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in virus titer at each time point</measure>
    <time_frame>From Day 1 pretreatment to Days 2, 3, 5, and 9</time_frame>
    <description>Virus titer is measured by tissue culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in virus RNA (RT-PCR) at each time point</measure>
    <time_frame>From Day 1 pretreatment to Days 2, 3, 5, and 9</time_frame>
    <description>Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) adjusted by baseline in virus titer</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Defined as AUC of change from baseline in virus titer. The AUC is calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) adjusted by baseline of virus RNA</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Defined as AUC of change from baseline in virus RNA. The AUC is calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of viral shedding by virus titer</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Defined as the time between the initiation of the study treatment and first time when the virus titer is below the limit of quantification (BLQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of viral shedding by virus RNA</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Defined as the time between the initiation of the study treatment and first time when the virus RNA is below the limit of quantification (BLQ) measured by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants whose symptoms have been alleviated at each time point</measure>
    <time_frame>Days 2, 3, 4, 5, 6, 9, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of the 4 systemic symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Defined as the time between the initiation of the study treatment and the alleviation of the 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of the 3 respiratory symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Defined as the time between the initiation of the study treatment and the alleviation of the 3 respiratory symptoms (cough, sore throat and nasal congestion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in composite symptom score at each time point</measure>
    <time_frame>Day 1 pretreatment to morning and evening on Days 2 to 9 and evening on Days 10 to 14</time_frame>
    <description>Defined as the change from Day 1 pretreatment (baseline) in the total score of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) as assessed by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever is defined as the time when the patient's self-measured axillary temperature becomes less than 37ºC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting normal temperature at each time point</measure>
    <time_frame>Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening</time_frame>
    <description>Defined as the percentage of patients whose axillary temperature drops to less than 37ºC after the initiation of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature at each time point</measure>
    <time_frame>Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of individual symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Defined as the time between the initiation of the study treatment and the alleviation of individual symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to preinfluenza health status</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Patients will be asked to record their preinfluenza health status (for someone your age and your health condition). Return to preinfluenza health status is defined as time from the initiation of the study treatment to the time to return to preinfluenza health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with influenza-related complications</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Defined as the percentage of patients in the analysis population who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 22 plus or minus 3 days</time_frame>
    <description>The incidence of AEs in patients with influenza after Baloxavir Marboxil, after oseltamivir, and after placebo.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1494</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 20 to 64 years will receive two or four 20-mg Baloxavir Marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four S 033188 placebo tablets on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 20 to 64 years will receive two or four S 033188 placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents: Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 19 years will receive two or four S 033188 20-mg tablets on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 12 to 19 years will receive two or four Baloxavir Marboxil placebo tablets on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir Marboxil</intervention_name>
    <description>2 to4 X 20-mg tablets taken orally</description>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
    <arm_group_label>Adolescents: Baloxavir Marboxil</arm_group_label>
    <other_name>S-033188</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Baloxavir Marboxil</intervention_name>
    <description>2 to4 X 20-mg tablets taken orally</description>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_label>Adolescents: Placebo</arm_group_label>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>75-mg capsules taken orally</description>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
    <other_name>Tamiflu®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Oseltamivir</intervention_name>
    <description>Placebo capsules matching oseltamivir 75-mg capsules</description>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are able to understand the study and comply with all study procedures,
             and willing to provide written informed consent/assent prior to the predose
             examinations appropriately. As for adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements

          2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed
             consent/assent form.

          3. Patients with a diagnosis of influenza virus infection confirmed by all of the
             following:

               1. Fever ≥ 38ºC (axillary) in the predose examinations or &gt; 4 hours after dosing of
                  antipyretics if they were taken

               2. At least one of the following general systemic symptoms associated with influenza
                  are present with a severity of moderate or greater

                    -  Headache

                    -  Feverishness or chills

                    -  Muscle or joint pain

                    -  Fatigue

               3. At least one of the following respiratory symptoms associated with influenza are
                  present with a severity of moderate or greater

                    -  Cough

                    -  Sore throat

                    -  Nasal congestion

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least one general or respiratory symptom

          5. Women of childbearing potential who agree to use a highly effective method of
             contraception for 3 months after the first dose of study drug

        Exclusion Criteria:

          1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).

          3. Patients with any of the following risk factors

               1. Women who are pregnant or within 2 weeks post-partum

               2. Residents of long-term care facilities (eg, welfare facilities for the elderly,
                  nursing homes)

               3. Chronic respiratory diseases including bronchial asthma

               4. Neurological and neurodevelopmental disorders including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, intellectual disability, moderate to severe developmental
                  delay, muscular dystrophy, or spinal cord injury)

               5. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms)

               6. American Indians and Alaskan natives

               7. Blood disorders (such as sickle cell disease)

               8. Endocrine disorders (including diabetes mellitus)

               9. Kidney disorders

              10. Liver disorders

              11. Metabolic disorders

              12. Compromised immune system (including patients receiving immunosuppressant
                  therapy, or those with cancer or human immunodeficiency virus [HIV] infection)

              13. Morbid obesity (body mass index [BMI] ≥ 40)

          4. Patients unable to swallow tablets or capsules.

          5. Patients who have previously received Baloxavir Marboxil.

          6. Patients weighing &lt; 40 kg

          7. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          8. Women who are breastfeeding or have a positive pregnancy test in the predose
             examinations. The following female patients who have documentation of either a or b
             below do not need to undergo a pregnancy test in the predose examinations:

               1. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or
                  more and confirmed by a follicle-stimulating hormone test) women

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral
             therapy at the predose examinations.

         10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir, or amantadine within 30 days prior to the predose
             examinations.

         11. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         12. Patients with severe underlying diseases.

         13. Patients with known creatinine clearance ≤ 60 mL/min.

         14. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <disposition_first_submitted>March 1, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 1, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 5, 2018</disposition_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu</keyword>
  <keyword>Baloxavir Marboxil</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>Tamiflu®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

